Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 968.28M |
| Revenue (ttm) | 9.85M |
| Net Income (ttm) | -109.22M |
| Shares Out | 48.68M |
| EPS (ttm) | -2.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,237 |
| Open | 19.76 |
| Previous Close | 19.75 |
| Day's Range | 19.33 - 20.23 |
| 52-Week Range | 3.97 - 24.17 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 44.88 (+125.6%) |
| Earnings Date | Aug 8, 2022 |
About PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohep... [Read more...]
Financial Performance
In 2021, PLRX's revenue was $7.57 million, a decrease of -81.89% compared to the previous year's $41.82 million. Losses were -$97.26 million, 134.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 44.88, which is an increase of 125.64% from the latest price.
News
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%
The mean of analysts' price targets for Pliant Therapeutics, Inc. (PLRX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 142%
The consensus price target hints at a 142.4% upside potential for Pliant Therapeutics, Inc. (PLRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...
2022 Roundtable: Our Favorite Picks Right Now
Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholang...
SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective αvß6 / αvß1 integrin inhibitor, has received Fa...
Could Pliant Therapeutics Stock Double Your Money?
Wall Street thinks this red-hot biotech stock has a lot more room to run.
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Pur...
SOUTH SAN FRANCISCO, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
What's Going On With Pliant Therapeutics Stock?
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% Monday on the compa...
Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?
Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren...
After-Hours Alert: Why Pliant Therapeutics Stock Is Moving
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% ...
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Why Pliant Therapeutics Stock Is Crushing It Today
A positive mid-stage trial readout in idiopathic pulmonary fibrosis is powering the biotech's stock higher.
Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?
Pliant Therapeutics (PLRX) stock is rocketing higher on Monday after revealing data from a Phase 2 clinical trial of PLN-74809. The post Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?
Why Are Pliant Therapeutics Shares Rallying Today?
Pliant Therapeutics Inc's (NASDAQ: PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints. The data demonstrated that PLN-74809 wa...
Pliant's stock gains 41% after sharing positive data about its fibrosis therapy candidate
Shares of Pliant Therapeutics Inc. PLRX, +1.37% jumped 41.6% in premarket trading on Monday after the company shared positive data from a Phase 2a clinical trial for its experimental idiopathic pulmonar...
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-7480...
PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Cl...
SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
- IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end 2022